GLP-1 Peptides — The Complete Research Reference

GLP-1 (glucagon-like peptide-1) is a hormone naturally produced by L-cells in the small intestine in response to food intake. It plays a central role in metabolic regulation: stimulating glucose-dependent insulin secretion from the pancreas, suppressing glucagon release (which prevents the liver from dumping stored glucose into the bloodstream), slowing gastric emptying to extend feelings of fullness, and acting on appetite centers in the hypothalamus to reduce hunger. In healthy individuals, GLP-1 is rapidly degraded by the enzyme DPP-4, giving it a half-life of only 2–3 minutes. The entire class of GLP-1 receptor agonist drugs was designed to resist this degradation and extend the hormone’s effects from minutes to days.

The history of GLP-1 drug development traces back to an unlikely source: the saliva of the Gila monster lizard. In 1992, researcher John Eng discovered a peptide called exendin-4 in Gila monster venom that shared 53% sequence homology with human GLP-1 but resisted DPP-4 degradation. This led to the development of exenatide, the first GLP-1 receptor agonist approved for type 2 diabetes in 2005. Pharmaceutical companies then engineered increasingly long-acting synthetic versions — from twice-daily exenatide to once-weekly semaglutide, which uses an albumin-binding fatty acid chain to achieve a 7-day half-life. The dual agonist tirzepatide added GIP receptor activation to the formula, and retatrutide went further with triple receptor agonism (GLP-1 + GIP + glucagon), producing the largest weight loss results ever seen in clinical trials.

Beyond the approved GLP-1 receptor agonists, a broader landscape of research peptides targets overlapping metabolic pathways. AOD-9604 is a modified fragment of human growth hormone (amino acids 177–191) that isolates the fat-metabolizing properties of hGH without affecting blood sugar or tissue growth. Tesamorelin is an FDA-approved GHRH analog that specifically targets visceral adipose tissue. MOTS-c, a mitochondrial-derived peptide, enhances cellular energy metabolism through AMPK activation — effectively mimicking some of the metabolic benefits of exercise. These compounds offer alternative or complementary approaches for researchers investigating metabolic optimization beyond direct GLP-1 receptor activation.

GLP-1 receptor agonists promote weight loss through four distinct, synergistic mechanisms that work together to create a significant and sustained reduction in caloric intake:

Unlike stimulant-based appetite suppressants that work through adrenaline pathways and carry risks of cardiovascular stress, dependency, and rebound weight gain, GLP-1 peptides work by mimicking a hormone your body already produces — which is why the side effect profile is fundamentally different. The primary side effects are gastrointestinal rather than cardiovascular.

The evolution of GLP-1 therapeutics follows a clear trajectory: each generation activates additional hormone receptors for increasingly potent metabolic effects. Understanding this spectrum is essential for comparing compounds in this class.

All GLP-1 receptor agonists share a broadly similar side effect profile, with gastrointestinal symptoms being the most common. Side effects are typically dose-dependent and most pronounced during the initial titration period.

Always consult a qualified healthcare professional before starting any GLP-1 receptor agonist. These are prescription medications in most jurisdictions and require medical supervision for safe use.